Corporate Media in U.S. Ignores Report N1H1 Vaccine Link to Guillain-Barré Syndrome

Corporate Media in U.S. Ignores Report N1H1 Vaccine Link to Guillain-Barré Syndrome







A Google News search this morning returns no mention of the
Guillain-Barré Syndrome link to the experimental H1N1 vaccine in the
U.S. media.

	28,000 people in the U.S. will participate in a government trial of the experimental H1N1 vaccine.

The story has made the rounds in the British press.
“The Health Protection Agency (HPA) has asked doctors to check for
increases in a brain disorder called Guillain-Barré syndrome (GBS) once
the national vaccination programme begins,” the Telegraph
reports. “According to the Mail on Sunday, two letters were posted
together to neurologists advising them of the concerns. The first, dated
July 29, was written by Professor Elizabeth Miller, head of the HPA’s
Immunization Department.”
The Times Online, Sky News, and the Daily Mail also ran stories on the
warning. Alternative news sites in the United States reported on the
link but the New York Times, the Washington Post, and other corporate
media sources are silent as of this morning.
28,000 people in the U.S. will participate in a government trial of the
experimental H1N1 vaccine. “Volunteers will be checked closely for any
side effects. They’ll also be monitored for Guillain-Barre syndrome,
which was reported in people who received a swine flu vaccine 33 years
ago. It’s a rare syndrome usually triggered by a viral infection, and no
one knows for sure if the vaccine is also a trigger,” KPBS reported on August 10.

Adult volunteers for the clinical trials will be recruited at 8
separate sites including Emory University in Atlanta, the University of
Maryland School of Medicine in Baltimore, Vanderbilt University in
Nashville, Baylor College of Medicine in Houston, Children’s Hospital
Medical Center in Cincinnati, Group Health Cooperative in Seattle, the
University Iowa in Iowa City, and St. Louis University, Deborah Shlian reported for the Examiner on July 28.

The initial tests will be of vaccines made by Sanofi-Pasteur, a
European company, and CLS Biotherapies, an Australian company that has
supplied seasonal flu shots in the U.S. for years. Novartis is also
conducting separate trials for FDA licensing.

Source:-
http://www.infowars.com/corporate-media-in-u-s-ignores-report-n1h1-vaccine-link-to-guillain-barre-syndrome/